Company Overview - Telo Genomics Corp. is a Toronto-based biotech company specializing in diagnostic and prognostic innovations through its proprietary multi-factor telomere analytics platform [1] - The company focuses on liquid biopsies and related technologies in oncology and neurological diseases, which are less invasive and more easily replicated than traditional diagnostic methods [5] - Telo Genomics has developed products that improve patient care by addressing the needs of pathologists, clinicians, academic researchers, and drug developers [5] Recent Developments - Guido Baechler, Executive Chairman, will present at the Small Cap Growth Virtual Investor Conference on December 9th, 2025 [1] - The company has initiated a multiple myeloma MRD clinical trial in collaboration with Cleveland Clinic Cancer Institute, utilizing Telo's 3D telomere analysis [8] - Telo Genomics has relocated to a larger, state-of-the-art clinical lab in the Greater Toronto Area [8] Clinical Applications - The lead application, Telo-MM, aims to provide actionable information for medical professionals treating Multiple Myeloma, a severe form of blood cancer [5] - Telo Genomics' technology has been validated in over 160 peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease [5] - The company presented interim data from its MM-MRD study at the American Society of Hematology Annual Meeting [8] Investor Engagement - The Virtual Investor Conferences (VIC) provide an interactive platform for publicly traded companies to present directly to investors [6] - The upcoming conference will allow real-time questions from investors, with an archived webcast available for those unable to attend live [2][3]